Skip to main content
logo
Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
1.515
-0.125 (-7.62%)
Aug 20, 2026, 4:00 PM EDT - Market closed

Neumora Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
2853041,7132,604--
Market Cap Growth
9.18%-82.24%-34.22%---
Enterprise Value
2211531,3742,090--
Last Close Price
1.511.7910.6017.05--

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
6.362.935.975.55--
P/TBV Ratio
6.392.935.975.55--

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
1.200.530.010.010.020.01
Net Debt / Equity Ratio
-1.43-1.23-1.06-0.98-0.97-1.01
Net Debt / EBITDA Ratio
0.310.541.162.453.175.10
Net Debt / FCF Ratio
0.350.621.662.733.015.34
Quick Ratio
4.215.6310.2918.0815.7317.59
Current Ratio
4.505.8710.5119.0516.3717.85
Return on Equity (ROE)
-187.11%-121.21%-64.48%-54.49%-32.67%-80.18%
Return on Assets (ROA)
-73.85%-58.11%-40.50%-25.50%-17.95%-16.01%
Return on Capital Employed (ROCE)
-211.60%-148.90%-91.80%-39.90%-30.50%-19.80%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-74.74%-77.89%-14.24%-9.06%--
FCF Yield
-63.42%-67.87%-10.73%-6.45%--
Buyback Yield / Dilution
-8.03%-2.52%-145.12%-138.99%-24.25%-68.46%
SEC Filings: 10-K · 10-Q